Remix Therapeutics
Our Science
Platform
Pipeline
REM-422
About Us
Our Story
Our People
Our Investors
Our Partners
Join Us
News
News
Press Releases
Publications
Clinical Trials
Our Science
Platform
Pipeline
REM-422
About Us
Our Story
Our People
Our Investors
Our Partners
Join Us
News
News
Press Releases
Publications
Clinical Trials
Contact
May | 3 | 2024
News
Remix Therapeutics doses first subjects in Phase I cancer treatment trials
Clinical Trials Arena
Read Article
Back to News
Media Contact
media@remixtx.com
Investor Contact
WILL O’CONNOR
Precision AQ
Will.OConnor@precisionaq.com